Isochlorogenic Acid C Alleviates Allergic Asthma via Interactions Between Its Bioactive Form and the Gut Microbiome
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26104864 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jing-Yi Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Fine Exploration and Intelligent Development of Coal Resources & School of Chemical and Environmental Engineering, China Uni…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Asthma, Chlorogenic Acid, Anti-Asthmatic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region, CAMS Innovation Fund for Medical Sciences, Tianshan Talent Training Program.
Abstract (Originalsprache)
The global prevalence of asthma is approximately 4.3%, and current asthma treatments focus on reducing symptoms, maintaining normal activity levels, and preventing the deterioration of lung function, rather than achieving a cure or complete prevention. We identified isochlorogenic acid C (ICGAC) as a potential natural medicine for the treatment of asthma. However, the bioavailability of ICGAC was low, ranging from 14.4% to 16.9%, suggesting the involvement of the gut microbiota. The full spectrum of ICGAC’s anti-asthmatic mechanism remains to be elucidated. This study investigated the mechanism by which ICGAC alleviates allergic asthma through the gut–lung axis. We discovered anti-asthma pathways and targets based on the selective regulation of lipid peroxidation and employed pharmacological tools to preliminarily validate their mechanisms and efficacy. To study the role of ICGAC in regulating the gut microbiota, we performed 16S rRNA gene sequencing and metabolite analysis. Furthermore, by combining molecular biology and lipid metabolomics, we elucidated the underlying anti-asthma mechanisms of ICGAC. The effective form of ICGAC varies between single and long-term administration. The oral administration of ICGAC enhances the gut-microbiota-derived production of short-chain fatty acids (SCFAs) as the active substances, modulates immune cell activity, influences the differentiation of T- and B-cells, and reduces airway inflammation. ICGAC also regulates the metabolic network of lipid mediators (LMs) and polyunsaturated fatty acids (PUFAs), thus exerting anti-inflammatory effects by modulating arachidonate lipoxygenase (ALOX) activity and LM levels. In addition, ICGAC enhanced the antioxidant response by upregulating the expression of glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11), and nuclear factor erythroid 2-related factor 2 (Nrf2), while inhibiting the release of interleukin-4 (IL-4), thereby suppressing asthma inflammation and IgE production. The anti-asthmatic mechanism of oral ICGAC involves the inhibition of lipid peroxidation by chlorogenic acid (CGA) and SCFAs produced by the gut microbiota. ICGAC suppresses asthma-associated inflammatory and oxidative stress responses through the upregulation of GPX4, SLC7A11, and Nrf2 in lung tissue. This study not only provides a solid foundation for the potential clinical use of ICGAC in asthma treatment but also offers novel insights for future research and therapeutic strategies targeting asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Fine Exploration and Intelligent Development of Coal Resources & School of Chemical and Environmental Engineering, China University of Mining and Technology-Beijing, Ding 11 Xueyuan Road, Beijin…
- Xinjiang Institute of Material Medica, Urumqi 830004, China.
- State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
ORCID-Profile: Yan-Xing Han, Tian-Le Gao
Förderung
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
- CAMS Innovation Fund for Medical Sciences
- Tianshan Talent Training Program
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Xu, J. Y., Rong, X. J., Shen, Z., Guo, Y. D., Zhang, Y. X., Ding, C. C., Wang, Y., Han, Y. X., Gao, T. L., & Tie, C. (2025). Isochlorogenic Acid C Alleviates Allergic Asthma via Interactions Between Its Bioactive Form and the Gut Microbiome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104864
Vancouver
Xu JY, Rong XJ, Shen Z, Guo YD, Zhang YX, Ding CC, et al. Isochlorogenic Acid C Alleviates Allergic Asthma via Interactions Between Its Bioactive Form and the Gut Microbiome. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104864
BibTeX
@article{Xu2025,
author = {Xu, Jing-Yi and Rong, Xiao-Juan and Shen, Zhen and Guo, Yun-Dan and Zhang, Yi-Xuan and Ding, Chen-Chen and Wang, Yi and Han, Yan-Xing and Gao, Tian-Le and Tie, Cai},
title = {Isochlorogenic Acid C Alleviates Allergic Asthma via Interactions Between Its Bioactive Form and the Gut Microbiome},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26104864}
}
EUVIMED